A few months ago we sat down with Cybin CEO Doug Drysdale for an informative interview about the company’s developmental programs. A main topic of discussion was their work with a new DMT compound, CYB-004, and its exciting therapeutic potential.
Since then, Cybin has continued to push the candidate forward, releasing positive preclinical data on the compound, including:
- Rapid onset, longer duration of action, and similar low variability achieved with single inhalation of CYB004 compared with IV DMT
- Inhaled CYB004 demonstrated more than 40% improved bioavailability over inhaled DMT
And today, we received news that the firm is continuing to aggressively pursue its DMT development with the acquisition of a major DMT study from Entheon Biomedical.
The study is the largest Phase 1 DMT trial to date and will greatly accelerate Cybin’s DMT program. The purchase price of the acquisition is $1,000,000 (CAD) + potential consulting service in the future (Entheon will continue to support the CYB004-E study and act as external consultants to Cybin).
The move will likely be a boon to Cybin’s CYB-004 trials, but what does it mean for Entheon, a firm once considered as a potential DMT pioneer? Stay tuned for more and see the full press release below.
Cybin Acquires DMT Clinical Study from Entheon Biomedical
06/07/2022
— Acquisition of largest Phase 1 DMT study conducted to date is expected to accelerate CYB004 program timeline by nine months —
— Phase 1 study evaluating pharmacokinetics/pharmacodynamics of DMT currently underway and will inform clinical path forward —
TORONTO–(BUSINESS WIRE)– Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™”, today announced that, through its wholly-owned subsidiary Cybin IRL Limited, it has entered into an agreement to acquire a Phase 1 N,N-dimethyltryptamine (“DMT”) study (the “Acquisition”) from Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (“Entheon”) to accelerate the clinical development path for CYB004, Cybin’s proprietary deuterated DMT molecule for the potential treatment of anxiety disorders.
The Phase 1 EBRX-101 study, now named CYB004-E, is being conducted in the Netherlands at the Centre for Human Drug Research, a leading independent foundation specializing in innovative early-stage clinical drug research, in 50 healthy volunteers who smoke tobacco – making it the largest Phase 1 DMT clinical study conducted to date. Pending the close of the Acquisition, the CYB004-E study is expected to yield essential safety and dosing optimization data and will replace Cybin’s planned pilot study for CYB004 that was expected to commence in the third quarter of 2022. Entheon will continue to support the CYB004-E study and act as external consultants to Cybin.
“The most precious commodity in drug development is time and acquiring this robust Phase 1 study already underway potentially accelerates the CYB004 development program by approximately nine months. The PK findings from the CYB004-E study should also help to inform the clinical path forward for this innovative and proprietary molecule,” said Doug Drysdale, Chief Executive Officer of Cybin. “This transaction also provides Cybin with access to a world-class research foundation and the privilege to work with the Entheon team, who offer a wealth of knowledge and expertise in this psychedelic class.”
The purchase price of the Acquisition is $1,000,000 (CAD), a portion of which will be a deposit with the balance payable on closing of the Acquisition. Up to an additional $480,000 (CAD) is payable for consulting services to be provided by Entheon for up to twelve months following the closing of the Acquisition. Pursuant to the Acquisition the Company will also enter into a data license agreement with Entheon that will permit Entheon to access certain data to support the Entheon IQ program. The Company expects the Acquisition to close within 30 days, subject to the completion of certain conditions and obtaining all necessary approvals.
“With our recent IND filing for CYB003, we are quickly becoming a multi-program clinical-stage company with four sponsored human trials underway in 2022. This is especially meaningful to our work to bring our innovative psychedelic-based therapies to people in need as quickly as possible. This is a truly exciting time for Cybin,” concluded Drysdale.
About the CYB004-E Study
The CYB004-E study is an adaptive, randomized, double-blind, placebo-controlled, single ascending dose study to evaluate the safety, pharmacokinetics (“PK”) and pharmacodynamics (“PD”) of a target-controlled intravenous infusion of DMT in healthy smokers.
Primary Objectives:
- Evaluate the safety of increasing doses of a single dose continuous DMT infusion over 90 minutes;
- Characterize the PK of a single dose DMT administered continuously over 90 minutes;
- Characterize the PD of a single dose DMT administered continuously over 90 minutes; and
- Establish the minimum DMT dose required to produce a psychedelic effect.
Pending results from the CYB004-E study, Cybin plans to evaluate CYB004 delivered via intravenous (“IV”) and via inhalation to determine the clinical path forward. Based on preclinical results reported by Cybin in April 2022, inhaled CYB004 demonstrated:
- Approximately 2000% improved bioavailability compared with orally administered DMT, which is known to have limited to no oral bioavailability;
- Approximately 41% improved bioavailability compared with inhaled DMT;
- Approximately 300% longer duration of effect when compared with IV DMT, indicating potential to extend therapeutic window; and
- Rapid onset of effect and similar low variability equivalent to IV DMT.
CYB004 is a new chemical entity for which a patent was issued by the U.S. Patent and Trademark Office in February 2022. The allowed claims include a range of deuterated forms of DMT and 5-MeO-DMT. The composition of matter patent is expected to expire in 2041 before consideration of any patent term extensions.
About Cybin
Cybin is a leading ethical biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. The Company is focused on progressing Psychedelics to Therapeutics by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders.
Investor & Media:
Leah Gibson
Vice President, Investor Relations & Strategic Communications
Cybin Inc.
irteam@cybin.com – or – media@cybin.com
Source: Cybin Inc.
